CELL REP 润色咨询

Cell Reports

出版年份:暂无数据 年文章数:10575 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.2% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2022-03-09 hppv587

    二审一个月了还没消息

    15

    展开15条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2021-01-30 12217aa9m85(暂无昵称)

    请问有转稿至cell reports的吗?命中率如何

    8

    展开8条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2017-08-26 xianjuema

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。

    6

    展开6条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2023-02-14 朋友一场 来自北京

    偏重的研究方向:肠道微生物与宿主互作
    经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?

    5

    展开5条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2022-07-15 yyyanz

    求问各位大大送审后修回机率大吗?

    5

    展开5条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2020-12-08 Yanzi2018

    请问各路大神,送审会通知吗?还是状态会变吗??

    5

    展开5条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2020-06-05 南大

    投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?

    5

    展开5条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2022-06-02 cindichaw

    年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2019-05-05 ms2638880249707848

    20190424投稿,
    20190426 with editor,
    20190504 review,

    4

    展开4条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921248, encodeId=00c292124868, content=请问有转稿至cell reports的吗?命中率如何, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64052305832, createdName=12217aa9m85(暂无昵称), createdTime=Sat Jan 30 04:17:53 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545925, encodeId=158454592530, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:个人感觉目前难度不是很大,相比eLife, PNAS有点差距,不过文章整体质量还是非常好。我的个人经历是投稿到Oncogene结果人家都不审稿,再投到了Cell Rep,小修后接受了,所以投稿的时候还要看是否遇到了欣赏你工作的编辑及审稿人吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08d965864, createdName=xianjuema, createdTime=Sat Aug 26 01:56:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向:肠道微生物与宿主互作<br>经验分享:12月16号投的,23号under review,今天2月14号了,快2个月了,还没有消息,各位一般一审多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1232664, encodeId=e8501232664c5, content=求问各位大大送审后修回机率大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/28/80e2808f5601a0210ea7aa90667fc272.jpg, createdBy=fe532106727, createdName=yyyanz, createdTime=Fri Jul 15 19:17:20 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906065, encodeId=a544906065ba, content=请问各路大神,送审会通知吗?还是状态会变吗??, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL7OEX1KSPDmCAR9PGNOrNjvBc2fqqANfyQkI7Zib3NVp23PgSyPZ0MWiaTUFKqZS600QTIgxTv6utQ/132, createdBy=36f32289964, createdName=Yanzi2018, createdTime=Tue Dec 08 16:59:36 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601471, encodeId=65d06014e1f6, content=投稿两周被拒,建议转投iscience,这个杂志怎么样,转投成功率高么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Fri Jun 05 10:16:03 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊,SA,NC之类的冲上不去,工作量挺大的,发了cell rep。感觉略亏了,但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿,<br> 20190426 with editor,<br> 20190504 review, , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向:molecular biology<br>经验分享:with editor已经8天了,什么原因呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=)]
    2022-05-27 sunyong_97

    偏重的研究方向:molecular biology
    经验分享:with editor已经8天了,什么原因呢?

    3

    展开3条回复
共354条页码: 1/36页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分